MedPath

ASAN FOUNDATION

ASAN FOUNDATION logo
🇰🇷South Korea
Ownership
Private
Established
1989-06-23
Employees
501
Market Cap
-
Website
https://ails.amc.seoul.kr

Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction

Not Applicable
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2020-04-29
Last Posted Date
2023-10-05
Lead Sponsor
Asan Medical Center
Target Recruit Count
62
Registration Number
NCT04367051
Locations
🇰🇷

Asan Medical Center, Seoul, Songpa-gu, Korea, Republic of

Effect of Thrombin-containing Collagen-based Hemostatic Matrix

Phase 4
Conditions
Pancreatic Tumor
Interventions
Drug: thrombin coated L-dopa contained collagen patch
Drug: flowable thrombin containing collagen hemostat matrix
First Posted Date
2020-04-22
Last Posted Date
2020-04-28
Lead Sponsor
Asan Medical Center
Target Recruit Count
60
Registration Number
NCT04357483
Locations
🇰🇷

Asan medical center, Seoul, Korea, Republic of

Home-based Cognitive Monitoring in MCI

Conditions
Mild Cognitive Impairment
Interventions
Diagnostic Test: home-based cognitive monitoring
First Posted Date
2020-04-17
Last Posted Date
2020-04-20
Lead Sponsor
Asan Medical Center
Target Recruit Count
40
Registration Number
NCT04350801
Locations
🇰🇷

Uijeongbu St. Mary's hospital, Uijeongbu, Korea, Republic of

Pharmacological Reduction of Right Ventricular Enlargement

Phase 3
Recruiting
Conditions
Tricuspid Regurgitation
Right Ventricular Dilatation
Interventions
Drug: Carvedilol+Empagliflozin
Drug: Placebo
Drug: Carvedilol
Drug: Empagliflozin
First Posted Date
2020-04-14
Last Posted Date
2023-07-21
Lead Sponsor
Asan Medical Center
Target Recruit Count
180
Registration Number
NCT04345796
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Analysis of the Microbiome in the Healthy Smokers and COPD Patients

Conditions
Pulmonary Disease, Chronic Obstructive
Microbiota
Interventions
Diagnostic Test: Obtain samples from sputum and feces
First Posted Date
2020-04-07
Last Posted Date
2020-04-07
Lead Sponsor
Asan Medical Center
Target Recruit Count
60
Registration Number
NCT04336423
Locations
🇰🇷

Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant

Conditions
Liver Transplant; Complications
Interventions
Procedure: LT
First Posted Date
2020-03-27
Last Posted Date
2020-03-27
Lead Sponsor
Asan Medical Center
Target Recruit Count
1199
Registration Number
NCT04324255
Locations
🇰🇷

Asan Medical center, Seoul, Korea, Republic of

B-line by Lung US in Patients With Acute Decompensated Heart Failure

Recruiting
Conditions
Heart Failure
Interventions
Diagnostic Test: Lung ultrasound
First Posted Date
2020-03-26
Last Posted Date
2023-02-02
Lead Sponsor
Asan Medical Center
Target Recruit Count
300
Registration Number
NCT04322851
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

MR-target Biopsy vs. TRUS-biopsy in Men With Suspicious Prostate Cancer

Not Applicable
Conditions
Prostate Cancer
Interventions
Device: Artemia
First Posted Date
2020-03-24
Last Posted Date
2020-03-25
Lead Sponsor
Asan Medical Center
Target Recruit Count
300
Registration Number
NCT04320147
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Hepatoma
Carcinoma, Hepatocellular
Interventions
Drug: Regorafenib/Nivolumab
First Posted Date
2020-03-17
Last Posted Date
2022-12-06
Lead Sponsor
Asan Medical Center
Target Recruit Count
42
Registration Number
NCT04310709
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

🇰🇷

Bundang CHA Hospital, Seongnam, Korea, Republic of

A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC

Phase 2
Recruiting
Conditions
Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
Interventions
Drug: Trastuzumab, Capecitabine and Cisplatin
First Posted Date
2020-03-16
Last Posted Date
2024-02-28
Lead Sponsor
Asan Medical Center
Target Recruit Count
28
Registration Number
NCT04309578
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath